Baxter Teams with MedicAlert to Add Glucose Monitoring Alert for Dialysis Patients


By: dhtest

Baxter International, Inc., which produces the peritoneal dialysis solution Extraneal (icodextrin), has teamed with MedicAlert Foundation International to encourage peritoneal dialysis patients to add a warning to their MedicAlert bracelets regarding the fact that icodextrin may cause false readings on non-specific glucose monitors. 

Peritoneal dialysis (PD) patients, approximately 50 percent of whom have diabetes, metabolize icodextrin into maltose. Because non-specific monitors do not differentiate among the types of sugar in the bloodstream, they read the maltose as glucose and consequently indicate higher levels of blood glucose than is actually the case. As a result, doctors may unknowingly misdiagnose hyperglycemia or administer incorrect doses of insulin to control blood sugars. 

Baxter’s collaboration with MedicAlert involves adding a warning to MedicAlert bracelets to alert healthcare providers that they must use glucose-specific testing and monitoring systems when dealing with PD patients. Baxter maintains a website where patients and healthcare providers can go to learn more about peritoneal dialysis treatments with Extraneal and the necessity for glucose-specific testing and monitoring.



Diabetes Health Medical Disclaimer
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.